Myelodysplastic/myeloproliferative neoplasm

This study tests an oral drug called pacritinib in people aged 12 and older with myelodysplastic syndromes (MDS) or related blood cancers (MDS/MPN). The goal is to find the best dose and see if it can shrink or control the disease. Participants take capsules twice daily for up to…

This early-stage trial is testing whether two drugs that lower metal levels in the body can help people with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) respond better to chemotherapy. The study will enroll 58 adults and aims to find the safest dose and check f…

This study tests whether giving a chemotherapy drug (decitabine) plus a targeted therapy (ruxolitinib, fedratinib, or pacritinib) before a stem cell transplant helps people with advanced myeloproliferative neoplasms (MPN) get to transplant and have better outcomes. About 25 adult…

This study is testing a new drug called BGB-11417 (sonrotoclax) in people with acute myeloid leukemia (AML), myelodysplastic syndromes (MDS), or related blood cancers. The drug works by blocking a protein that helps cancer cells survive. The trial will give the drug alone or toge…

This study tests a combination of three drugs—ivosidenib, venetoclax, and azacitidine—in people with blood cancers like acute myeloid leukemia (AML) that have a specific IDH1 mutation. The goal is to see if the combo is safe and works better than current treatments. About 96 adul…

This phase 2 trial tests a drug called olutasidenib combined with other targeted therapies for people with relapsed or hard-to-treat blood cancers that have a specific IDH1 mutation plus other signaling mutations. The study aims to see how safe and tolerable these drug combinatio…

This phase 2 trial compares a drug combo (ASTX727 plus iadademstat) against ASTX727 alone for people with advanced myeloproliferative neoplasms (MPNs), a group of rare blood cancers. The study aims to see if adding iadademstat improves complete response rates. However, the trial …

This study tests a new antibody called axatilimab, given with or without the chemotherapy drug azacitidine, for people with advanced myeloproliferative neoplasms (MPN), MPN/MDS overlap, or high-risk chronic myelomonocytic leukemia (CMML). The goal is to find the safest dose and s…

This phase 2 trial tests whether adding the drug ruxolitinib to standard care can prevent graft-versus-host disease (GVHD) in older patients with myelofibrosis or MDS/MPN overlap syndromes who receive a donor stem cell transplant. About 50 participants will get ruxolitinib before…

This study tests an experimental inhaled drug called PUL-042 in 100 people with blood cancers or who have had a stem cell transplant and have a viral lung infection. Participants receive either the drug or a placebo three times over six days. The goal is to see if PUL-042 can red…

This phase 2 trial tests whether giving patients their own personalized natural killer (NK) cells after chemotherapy and a cord blood transplant can help kill any remaining cancer cells. The study includes 100 people with various blood cancers like leukemia, lymphoma, and multipl…

This study provides unlicensed cord blood units for transplant to children and adults with blood cancers, immune disorders, and other serious diseases. The goal is to see how well patients recover their white blood cells after the transplant. By making more cord blood units avail…

This early-stage study tests a new oral drug called onvansertib for people with chronic myelomonocytic leukemia (CMML) or related blood cancers that have returned or stopped responding to standard treatments. The drug works by blocking a protein that helps cancer cells grow. The …

This early-phase trial tests whether specially trained natural killer (NK) cells, called CIML NK cells, along with interleukin-2 (IL-2), can safely prevent leukemia from coming back after a stem cell transplant. The study enrolls 15 adults with high-risk acute myeloid leukemia, m…

This study tests whether alternating two different drug combinations can help control higher-risk myelodysplastic syndrome (MDS) and chronic myelomonocytic leukemia (CMML). About 60 adults who have not responded to or relapsed after standard treatment will receive cladribine, low…

This study tests a new daily pill called JBI-802 in people with certain blood cancers (myeloproliferative neoplasms and MDS/MPN) who have too many platelets. The trial has two phases: first, finding a safe dose in about 30 adults, then checking if it works. Participants take the …

This early-phase study tests whether adding hyperbaric oxygen therapy (breathing pure oxygen in a pressurized chamber) to standard stem cell transplant preparation is safe and helps recovery. It involves 24 adults with various blood cancers, such as leukemia and myelofibrosis. Th…

This early study tests a new way of giving two FDA-approved drugs (5-azacitidine and decitabine) for myelodysplastic syndromes (MDS), a type of bone marrow failure. Instead of standard doses, the drugs are given at low doses on alternating weeks to try to overcome resistance. Abo…

This early-phase trial tests a new cell therapy for people with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) who still have small amounts of cancer cells after standard treatment. The therapy uses the patient's own blood cells, armed with a special antibody to t…

This early-stage study tests a new oral drug, LP-118, in up to 100 adults with blood cancers like lymphoma, leukemia, or myeloma that returned or didn't respond to prior therapy. The main goals are to find the safest dose and see if the drug can shrink tumors or slow the disease.…

This study is testing an experimental oral drug called ASTX030 (a combination of azacitidine and cedazuridine) for people with certain blood cancers like myelodysplastic syndromes (MDS), acute myeloid leukemia (AML), and chronic myelomonocytic leukemia (CMML). The drug is given a…

This study tests new combinations of drugs for people with MDS/MPN, a group of rare blood cancers. The goal is to find safe and effective doses of these drug combos to better control the disease. About 94 adults will take part, receiving an oral drug called ASTX727 plus another t…

This study is for people with certain blood cancers (like acute myeloid leukemia) that have a specific genetic change called a FLT3 mutation. The cancers have either come back or not responded to prior treatment. The trial tests a combination of three drugs—azacitidine, venetocla…

This early-phase trial tests a new drug called iadademstat combined with a standard chemotherapy (azacitidine) in people with myelodysplastic syndrome (MDS), a bone marrow disorder. The main goal is to find the safest dose for future studies. About 12 adults with higher-risk MDS …

This early-phase trial tests whether adding the drug momelotinib to standard azacitidine treatment can better control rare blood cancers like chronic myelomonocytic leukemia and chronic neutrophilic leukemia. About 18 adults will take momelotinib pills daily plus azacitidine inje…

This phase 3 trial tests whether adding the targeted drug venetoclax to standard chemotherapy (fludarabine and melphalan) before a donor stem cell transplant can improve outcomes for patients over 50 with acute myeloid leukemia or myelodysplastic syndrome. The study will compare …

This early-stage trial is testing whether adding two drugs, decitabine and venetoclax, to a standard reduced-intensity stem cell transplant can safely help control high-risk myeloid cancers like acute myeloid leukemia. About 20 adults aged 18-75 with a matched donor will receive …

This early-phase study tests a combination of two drugs, selumetinib and azacitidine, in adults with higher-risk blood cancers like MDS and myelofibrosis. The main goal is to find the safest dose of selumetinib when given with standard azacitidine and to monitor side effects. Par…

This study looks at a new genetic test called Caris Chromoseq for people with certain blood cancers (acute myeloid leukemia, myelodysplastic syndrome, or myeloproliferative neoplasms). The test scans the entire genome to help classify the cancer and guide risk assessment. Researc…

This trial tests a program called ACT, which trains doctors and nurses to have compassionate, structured conversations with blood cancer patients and their families about end-of-life care. The goal is to help patients understand their prognosis and make informed decisions, potent…

This study tests whether tranexamic acid (TXA), a drug that prevents blood clots from breaking down, can safely reduce bleeding in people with myelodysplastic syndromes (MDS) or acute myeloid leukemia (AML). About 75 outpatients receiving less-intensive chemotherapy will be rando…

This study tests a telehealth program that helps older adults (60+) with blood cancers like leukemia or MDS talk to their doctors about their care wishes. The program also helps them fill out advance directive forms. Researchers want to see if it improves communication and reduce…

Researchers in Italy are building a large registry of adults newly diagnosed with myelodysplastic syndromes, a group of blood cancers where the bone marrow does not make enough healthy blood cells. The study will collect data on up to 10,000 people to measure how many new cases o…

This study follows people with myelodysplastic syndromes (MDS) for up to 20 years to understand how the disease changes over time. Researchers will collect blood, bone marrow, and other samples from 1,100 participants, including healthy donors. The goal is to learn more about MDS…

This research study creates a registry of older adults with cancer to collect information about their health, treatments, and outcomes. Participants complete a geriatric assessment and allow researchers to follow their medical records. The goal is to better understand how cancer …

This study is for 80 adults with blood cancers like MDS or AML who are starting treatment. Participants wear a smartwatch and answer questionnaires to track their activity, symptoms, and quality of life. The goal is to help doctors better understand when patients need blood trans…

This long-term observational study is enrolling 5,000 adults with myeloproliferative neoplasms (MPNs)—rare blood cancers like polycythemia vera and myelofibrosis. Researchers will collect health records, patient surveys, and insurance data over at least five years to track sympto…

This study collects blood, tissue, and body fluid samples from up to 15,000 people with blood cancers or related disorders. The samples are stored in a central lab for future research on diagnosis, prognosis, and immune monitoring. Participants do not receive any treatment as par…